CD79B 靶点蛋白|抗体药物|临床药物信息

CD79B信息

英文名称：B-cell antigen receptor complex-associated protein beta chain
中文名称：B细胞抗原受体复合物相关蛋白β链
靶点别称：B-Cell Antigen Receptor Complex-Associated Protein Beta Chain，B29，Immunoglobulin-associated B29 protein，Ig-beta，B-cell-specific glycoprotein B29，CD79B，CD79b Molecule，CD79b Molecule， Immunoglobulin-Associated Beta，IGB，CD79B Antigen (Immunoglobulin-Associated Beta)，CD79b Antigen，AGM6

上市药物数量：1
临床药物数量：5
最高研发阶段：批准上市

CD79B产品列表

筛选结果

产品库

在线 (9)

物种

标签

属性

Protein (9)

标记

货号	物种	产品描述
CDB-C52H3	Cynomolgus	Cynomolgus CD79B Protein, His Tag (MALS verified)
CDB-C82E5	Cynomolgus	Biotinylated Cynomolgus CD79B Protein, His,Avitag™
CDB-H5259	Human	Human CD79B Protein, Fc Tag
CDB-H52H3	Human	Human CD79B Protein, His Tag (MALS verified)
CDB-H82E3	Human	Biotinylated Human CD79B Protein, His,Avitag™ (MALS verified)
CDB-HP2H6	Human	PE-Labeled Human CD79B Protein, His Tag (Site-specific conjugation)
CDB-M5253	Mouse	Mouse CD79B Protein, Fc Tagr (MALS verified)
CDB-M52H3	Mouse	Mouse CD79B Protein, His Tag (MALS verified)
CDB-M52H4	Mouse	Mouse CD79B Protein, His Tag, low endotoxin (MALS verified)

CDB-C82E5|Biotinylated Cynomolgus CD79B Protein, His,Avitag™

150XXXXXXX2

0人赞

根据文献查阅及实验目的，选择了对照实验蛋白，acro买过了很多蛋白，用的放心，质量有保障，目前做出来的实验结果也符合预期
2023-04-14

CDB-H82E3|Biotinylated Human CD79B Protein, His,Avitag™ (MALS verified)

150XXXXXXX2

0人赞

应实验要求，对比各种商家，出于对老用户的信任，选择acro的蛋白，相对品质有保证，目前做出来的实验数据误差较小，非常理想
2023-04-14

CD79B分子别名

CD79b,B29,IGB,Ig-beta

CD79B分子背景

B-cell antigen receptor complex-associated protein beta chain (CD79b) is also known as B-cell-specific glycoprotein B29, Ig-beta,Immunoglobulin-associated B29 protein, B29 and IGB, which is a single-pass type I membrane protein containing one Ig-like V-type ( immunoglobulin-like ) domain and one ITAM domain.CD79b is required in cooperation with CD79A for initiation of the signal transduction cascade activated by the B-cell antigen receptor complex (BCR).CD79b can enhance phosphorylation of CD79A, possibly by recruiting kinases which phosphorylate CD79A or by recruiting proteins which bind to CD79A and protect it from dephosphorylation. Defects in CD79b are the cause of agammaglobulinemia type 6 (AGM6) that is a primary immunodeficiency characterized by profoundly low or absent serum antibodies and low or absent circulating B cells due to an early block of B-cell development.

CD79B上市药物信息

英文名称	中文名称	研发代码	研发阶段	公司	最早商品名	最早批准国家	最早适应症	最早批准公司	最早批准日期	适应症	临床试验
Polatuzumab vedotin	维博妥珠单抗	RO-5541077; RO-5541077-000; FCU-2711; DCDS-4501A; RG-7596	批准上市	Seattle Genetics Inc, 基因泰克	Polivy	Mainland China(BOAO LECHENG)	弥漫性大B-细胞淋巴瘤	Roche Registration Gmbh	2019-06-10	B-细胞淋巴瘤, 弥漫性大B-细胞淋巴瘤, 滤泡中心淋巴瘤, 淋巴瘤, 非霍奇金淋巴瘤, 慢性淋巴细胞白血病	详情

CD79B临床药物信息

英文名称	研发代码	研发阶段	公司	适应症	临床试验
TolDCB29		临床二期	Umc Utrecht	类风湿关节炎	详情
CD19/79b Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute)	bi-4SCAR CD19/79b	临床二期	深圳市免疫基因治疗研究院	B-细胞淋巴瘤	详情
CD79b CAR-T cell therapy (Yake Biotechnology)		临床一期	浙江大学	急性淋巴细胞白血病, 非霍奇金淋巴瘤, 双表型急性白血病	详情
PRV-3279	MGD-010; PRV-3279; CD32BxCD79B	临床二期	Macrogenics Inc	药物相关的副作用和不良反应	详情
NBT-508		临床一期	上海新理念生物医药科技有限公司	B-细胞淋巴瘤, 非霍奇金淋巴瘤	详情

会议日历

会议一览

CD79B